Diagnos wins Saudi FDA marketing authorization for CARA retinal AI system

• Diagnos received Saudi SFDA marketing authorization for its CARA retinal image analysis system.
• Saudi-licensed CARA version includes AI detection algorithms for diabetic retinopathy, age-related macular degeneration.
• Authorization opens commercialization in Saudi Arabia via local distributor Kanhoor Medical.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Diagnos Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131421PRIMZONEFULLFEED9809791) on August 13, 2026, and is solely responsible for the information contained therein.